Consun Pharmaceutical Group（CPHG.F）株式概要コンスン・ファーマシューティカル・グループ・リミテッドは、中華人民共和国において漢方薬および医療用造影剤製品の研究開発、製造、販売を行っている。 詳細CPHG.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績6/6財務の健全性6/6配当金4/6報酬当社が推定した公正価値より62.8%で取引されている 収益は年間11.79%増加すると予測されています 過去1年間で収益は18.4%増加しました リスク分析株式の流動性は非常に低い 不安定な配当実績 すべてのリスクチェックを見るCPHG.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.6541.3% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture06b2016201920222025202620282031Revenue CN¥6.0bEarnings CN¥1.9bAdvancedSet Fair ValueView all narrativesConsun Pharmaceutical Group Limited 競合他社InnovivaSymbol: NasdaqGS:INVAMarket cap: US$1.6bHarmony Biosciences HoldingsSymbol: NasdaqGM:HRMYMarket cap: US$1.8bPhibro Animal HealthSymbol: NasdaqGM:PAHCMarket cap: US$1.4bANI PharmaceuticalsSymbol: NasdaqGM:ANIPMarket cap: US$1.7b価格と性能株価の高値、安値、推移の概要Consun Pharmaceutical Group過去の株価現在の株価HK$1.6552週高値HK$2.0052週安値HK$1.65ベータ0.611ヶ月の変化0%3ヶ月変化-17.50%1年変化47.32%3年間の変化n/a5年間の変化n/aIPOからの変化58.14%最新ニュースお知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.最新情報をもっと見るRecent updatesお知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.お知らせ • Apr 08Consun Pharmaceutical Group Limited Announces Executive and Committee ChangesConsun Pharmaceutical Group Limited announced that with effect from 8 April 2025, Mr. Young Yuk Chuen David ("Mr. Young") has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the "ESG Committee"); and Mr. Duan Weiwu (" Mr. Duan ") has been appointed as an independent non-executive Director, and a member of the audit committee (the "Audit Committee") and the nomination. Mr. Young Yuk Chuen David, aged 27, has obtained his bachelor's degree of science,in operations management and management and leadership from Boston College in May 2020 and his master's degree in management from Institut Européen d'Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group's international investment projects and development for overseas business. Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023. Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guidoz Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).Mr. Duan Weiwu aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng Guangzhou office of Beijing Dacheng Law Offices, LLP since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm in 2016. Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (now known as Zhongnan University of Economics and Law in 1999 with and his master's degree in law from Sun Yat-sen University in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency. The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee.お知らせ • Mar 26+ 1 more updateConsun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025Consun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025.お知らせ • Mar 13Consun Pharmaceutical Group Limited Announces First Cohort of Subjects Dosed for A Phase 1 Clinical Trial of SK-08 TabletConsun Pharmaceutical Group Limited announced that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed. Chronic kidney disease ("CKD") represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families. SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis. In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD. The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025Consun Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025お知らせ • Feb 25Consun Pharmaceutical Group Limited Announces CFO ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025, Mr. Fang Peicheng, formerly the vice president and chief financial officer of the Group, ceased to concurrently serve as Chief Financial Officer and continued to hold the position of vice president of the Group. Ms. Chen has been appointed as the Chief Financial Officer with effect from 24 February 2025. Ms. Chen Yujun served as an independent non-executive Director and among others, acted as the chairlady of the Audit Committee with appropriate professional qualifications and accounting expertise, from 31 May 2019 to immediately prior to the Resignation.お知らせ • Feb 24Consun Pharmaceutical Group Limited Announces Board and Committee ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025: Ms. Chen Yujun has resigned as an independent non-executive Director, and ceased to be the chairlady of the audit committee, and a member of the nomination committee, the remuneration committee and the environmental, social and governance committee and Mr. Li Zhuoguang has been appointed as an independent non-executive Director, the chairman of the Audit Committee, and a member of the Nomination Committee, the Remuneration Committee and the ESG Committee in place of Ms. Chen. The Resignation took effect from 24 February 2025, due to the reallocation of responsibilities in the Group's management. The Appointment took effect from 24 February 2025. Mr. Li, aged 42, has around 20 years of experience in audit and accounting works in the PRC. Mr. Li has been working for GUANGZHOU HEYGEARS IMC. INCas an executive director and assistant to the chairman of the board since August 2023. From January 2013 to June 2023, Mr. Li worked for Jiumaojiu International Holdings Limited,a company whose shares are listed on the Stock Exchange (stock code: 9922), and his last position was executive director and chief financial officer of Jiumaojiu and vice president of Guangzhou Jiumaojiu Catering Chain Co. Ltd. He worked at Tianji Real Estate Development (Shenzhen) Co., Lt, a real property development company as vice financial controller from April to December 2012 and KPMG Huazhen LLP as manager dfrom June 2005 to April 2012. Mr. Li became a member of the Chinese Institute of Certified Public Accountants in August 2008. He graduated from Sun Yat-sen University in July 2005 with a bachelor's degree in English.株主還元CPHG.FUS PharmaceuticalsUS 市場7D0%-0.1%-0.3%1Y47.3%38.7%26.7%株主還元を見る業界別リターン: CPHG.F過去 1 年間で36.1 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: CPHG.F過去 1 年間で23.3 % の収益を上げたUS市場を上回りました。価格変動Is CPHG.F's price volatile compared to industry and market?CPHG.F volatilityCPHG.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.0%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.2%安定した株価: CPHG.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCPHG.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19973,115Meng Anchinaconsun.comコンスン・ファーマシューティカル・グループ・リミテッドは、中華人民共和国において、漢方薬および医療用造影剤製品の研究開発、製造、販売を行っている。コンスン製薬とユーリン製薬の2つのセグメントで事業を展開。同社は、慢性腎臓病治療用の尿毒症クリアランス顆粒、蛋白尿治療用のイーシェンフアシ粒子、糖尿病性腎臓病治療用の中医学、神経中枢、胃、胸、骨盤腔、四肢、腎機能評価用のガドペンテト酸ジメグルミン注射剤、神経放射線学、血管造影、尿路造影用のイオパミドール注射剤、超音波マイクロバブル造影剤製品を提供している。また、鉄-デキストリン内服液「Yuanli Kang」、エリスロマイシンエストール酸塩懸濁液「Yibao Yuan」、塩酸セチリジン内服液「Yuantong Ning」、子宮筋腫出血、長期弛緩性下痢、月経間出血、避妊リング使用後の出血、痔出血、鼻出血を治療するカプセル「Zhixueling」なども提供しています；月経不順、更年期の月経不順、肝鬱血虚による月経時の腹痛に効く「ジン月経困難錠」、女性膣内の黄色ブドウ球菌、カンジダ・アルビカンス、エシェリヒア・コリに効く「抗菌フジエローション」。骨気液、リウマチ、感冒、頭痛、胃痛、心気痛、胃腔・胆のうの痛みを治療する雲翔鎮痛チンキ、血液循環を活性化し、瘀血を散らす三七壮春カプセル；柴胡清肝湯カプセル・錠剤、皮膚疾患用軟膏「ペオノール軟膏」、肝胆膵剤「地黄丸」「複方地黄丸」「清肝丸」、「地黄丸甘草丸」「五君子壇顆粒」などがある。また、胃腸薬、滋養強壮薬などの医薬品も提供している。1997年に設立され、本社は中華人民共和国の広州市にある。もっと見るConsun Pharmaceutical Group Limited 基礎のまとめConsun Pharmaceutical Group の収益と売上を時価総額と比較するとどうか。CPHG.F 基礎統計学時価総額US$1.83b収益（TTM）US$156.64m売上高(TTM)US$496.54m11.7xPER（株価収益率3.7xP/SレシオCPHG.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CPHG.F 損益計算書（TTM）収益CN¥3.42b売上原価CN¥750.24m売上総利益CN¥2.67bその他の費用CN¥1.59b収益CN¥1.08b直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）1.28グロス・マージン78.05%純利益率31.55%有利子負債／自己資本比率4.1%CPHG.F の長期的なパフォーマンスは？過去の実績と比較を見る配当金4.7%現在の配当利回り52%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/04 03:09終値2026/01/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Consun Pharmaceutical Group Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Zhuhong ChenChina Merchants Securities (HK) Co., Ltdnull nullCMB International Securities LimitedWai Ming KongDBS Bank Ltd2 その他のアナリストを表示
お知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.
お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026
お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.
お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.
お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.
お知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.
お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026
お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.
お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.
お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.
お知らせ • Apr 08Consun Pharmaceutical Group Limited Announces Executive and Committee ChangesConsun Pharmaceutical Group Limited announced that with effect from 8 April 2025, Mr. Young Yuk Chuen David ("Mr. Young") has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the "ESG Committee"); and Mr. Duan Weiwu (" Mr. Duan ") has been appointed as an independent non-executive Director, and a member of the audit committee (the "Audit Committee") and the nomination. Mr. Young Yuk Chuen David, aged 27, has obtained his bachelor's degree of science,in operations management and management and leadership from Boston College in May 2020 and his master's degree in management from Institut Européen d'Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group's international investment projects and development for overseas business. Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023. Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guidoz Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).Mr. Duan Weiwu aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng Guangzhou office of Beijing Dacheng Law Offices, LLP since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm in 2016. Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (now known as Zhongnan University of Economics and Law in 1999 with and his master's degree in law from Sun Yat-sen University in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency. The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee.
お知らせ • Mar 26+ 1 more updateConsun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025Consun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025.
お知らせ • Mar 13Consun Pharmaceutical Group Limited Announces First Cohort of Subjects Dosed for A Phase 1 Clinical Trial of SK-08 TabletConsun Pharmaceutical Group Limited announced that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed. Chronic kidney disease ("CKD") represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families. SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis. In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD. The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025Consun Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025
お知らせ • Feb 25Consun Pharmaceutical Group Limited Announces CFO ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025, Mr. Fang Peicheng, formerly the vice president and chief financial officer of the Group, ceased to concurrently serve as Chief Financial Officer and continued to hold the position of vice president of the Group. Ms. Chen has been appointed as the Chief Financial Officer with effect from 24 February 2025. Ms. Chen Yujun served as an independent non-executive Director and among others, acted as the chairlady of the Audit Committee with appropriate professional qualifications and accounting expertise, from 31 May 2019 to immediately prior to the Resignation.
お知らせ • Feb 24Consun Pharmaceutical Group Limited Announces Board and Committee ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025: Ms. Chen Yujun has resigned as an independent non-executive Director, and ceased to be the chairlady of the audit committee, and a member of the nomination committee, the remuneration committee and the environmental, social and governance committee and Mr. Li Zhuoguang has been appointed as an independent non-executive Director, the chairman of the Audit Committee, and a member of the Nomination Committee, the Remuneration Committee and the ESG Committee in place of Ms. Chen. The Resignation took effect from 24 February 2025, due to the reallocation of responsibilities in the Group's management. The Appointment took effect from 24 February 2025. Mr. Li, aged 42, has around 20 years of experience in audit and accounting works in the PRC. Mr. Li has been working for GUANGZHOU HEYGEARS IMC. INCas an executive director and assistant to the chairman of the board since August 2023. From January 2013 to June 2023, Mr. Li worked for Jiumaojiu International Holdings Limited,a company whose shares are listed on the Stock Exchange (stock code: 9922), and his last position was executive director and chief financial officer of Jiumaojiu and vice president of Guangzhou Jiumaojiu Catering Chain Co. Ltd. He worked at Tianji Real Estate Development (Shenzhen) Co., Lt, a real property development company as vice financial controller from April to December 2012 and KPMG Huazhen LLP as manager dfrom June 2005 to April 2012. Mr. Li became a member of the Chinese Institute of Certified Public Accountants in August 2008. He graduated from Sun Yat-sen University in July 2005 with a bachelor's degree in English.
